DOCSLIB.ORG

Development of the Medicines Optimisation Assessment Tool (MOAT)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Development of the Medicines Optimisation Assessment Tool (MOAT) Department of Practice and Policy UCL School of Pharmacy PhD Thesis – University College London Development of the Medicines Optimisation Assessment Tool (MOAT) Targeting hospital pharmacists' input to reduce risks and improve patient outcomes Cathy Anne Geeson NIHR Clinical Doctoral Research Fellow Pharmacy Department Luton and Dunstable University Hospital 1 Declaration I, Cathy Geeson confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Signature: Date: 2 Abstract Abstract Background Medicines optimisation is a key role for hospital pharmacists, but with ever-increasing demands on services, there is a need to increase efficiency while maintaining patient safety. The aim of this study was to use prognostic modelling to develop a prediction tool, the Medicines Optimisation Assessment Tool (MOATTM), to target patients most in need of pharmacists’ input while in hospital. Methods and analysis Patients from adult medical wards at two UK hospitals were prospectively included into this cohort study between April and November 2016. Data on medication related problems (MRPs) were collected by pharmacists at the study sites as part of their routine daily clinical assessment of patients. Data on potential risk factors, such as polypharmacy and use of ‘high-risk’ medicines, were collected retrospectively from the information departments at the study sites, laboratory reporting systems and patient medical records. Multivariable logistic regression was used to determine the relationship between potential risk factors and the study outcome, namely preventable MRPs that were at least moderate in severity. A simplified electronic scoring system (the MOAT) was then developed. Results Among 1,503 eligible patient admissions, 610 (40.6%) experienced the study outcome. Eighteen risk factors were pre-selected for MOAT development, with 11 variables retained in the final model. The MOAT demonstrated fair predictive performance (concordance index 0.66), and good calibration. The decision threshold between ‘low’ and ‘medium-risk’ patients has a sensitivity of 90% (specificity 30%). The sensitivity for the threshold between ‘medium’ and ‘high-risk’ patients is 66% (specificity 61%). Decision curve analysis suggests that the MOAT has potential to be clinically useful across a wide range of predicted risk probabilities (from approximately 15% to 70%). Conclusions The MOAT has potential to predict those patients most at risk of moderate or severe preventable MRPs. External validation will be required to establish predictive accuracy in a new group of patients. 3 Impact statement Impact statement The work presented in this thesis has the potential to be put to beneficial use both outside and inside academia. Each of these is discussed below, together with proposed timescales and methods for impact realisation. Impact on clinical practice In terms of potential impact of this research outside academia, the main output is the Medicines Optimisation Assessment Tool (MOATTM) itself, which was developed with the aim of increasing the efficiency of hospital pharmacy services, reducing risks and improving patient outcomes. Once fully validated, the MOAT has the potential to impact on professional practice and patient safety. The intention was for the MOAT to be adopted widely into clinical practice, therefore if generalisability and clinical effectiveness are demonstrated, the MOAT has the potential to be used across the UK, and potentially more widely; I have already received an expression of interest from a pharmacist in Australia regarding external validation of the MOAT within her clinical setting. Impact within this research area This study has also created knowledge that may inform future research in this field. This includes: consensus views on potential risk factors associated with medication related problems (MRPs) in hospitalised patients; data on MRP occurrence in adult medical patients in UK hospitals. More specifically, the prevalence of MRPs and moderate or severe preventable MRPs, and their breakdown by MRP sub-categories; quantification of the potential variability in MRP identification by hospital pharmacists; the views of practising pharmacy clinicians on the requirements of a predictive tool, including presentation and usability. My academic supervisors at UCL have offered a place to a prospective PhD candidate to progress work in this area; if accepted, I have been asked to be a clinical advisor. Realisation of impact While the academic knowledge created by this research has potential to be used immediately, further research will be required prior to implementation of the MOAT into 4 Impact statement routine practice. This will include external validation to assess predictive accuracy in a new sample of patients, and impact and implementation studies. I estimate this will take three to four years, dependant on funding opportunities. Initially I intend to raise awareness of the findings of this study through dissemination via presentations at professional, academic and scientific meetings and conferences, and submission for publication in peer-reviewed journals. I also plan to present at relevant patient / public meetings at the study sites, and to work with the patient and public members of the project steering group to develop a wider public dissemination strategy. I hope to secure further funding to validate the MOAT, and once fully validated I would aim to work with key decision makers, such as the Head of Research at the Royal Pharmaceutical Society, and Medication Safety Team at NHS England to advise on further dissemination and adoption of the MOAT into practice. There is also potential to work with software developers to integrate the MOAT into automated systems such as electronic health records systems, permitting automated risk assessments in ‘real-time’, further supporting implementation into clinical environments. 5 Acknowledgments Acknowledgments First, I would like to give my heartfelt thanks to Professor Bryony Dean Franklin and Dr Li Wei for their unwavering support, guidance and encouragement. It has been an absolute privilege to work under your supervision. In particular, I would like to thank Professor Bryony Dean Franklin who is a truly inspirational role model! I am sincerely grateful to Dr Mary Evans and Lindsay Smith for their clinical supervision, and for permitting this research to take place within their organisations. I would also like to thank the pharmacy staff involved in data collection; your dedication and combined enthusiasm were a tremendous support. Additional thanks go to Jack Glendenning, Colin Merrill, Andy Finch and Alan Osman for their support with technical aspects of data collection. I am also particularly grateful to Sehrush Hussain and Shahnaz Begum for their assistance with the simulated medication related problem (MRP) identification exercise, and to members of the expert panel, Sue Lee, Dr Siva Puthrasingam and Ann Williams; your expertise and experience were greatly appreciated. My sincere thanks also go to Aneesh Khurana for his technical input into the development of the electronic Medicines Optimisation Assessment Tool (MOATTM) scoring system. Similarly, I am indebted to the pharmacists and clinical pharmacy technicians who participated in the assessment of the MOAT’s clinical credibility. I would also like to recognise the patient and public members of the MOAT project steering group: Helen Clothier, Marie-France Capon, Brian Smith, Derek Wright and Tom Drabble. These amazingly supportive people ensured that a patient / carer perspective remained prominent during the research, while providing encouragement and valuable advice throughout. I would also like to thank the National Institute for Health Research for the opportunity to undertake a Clinical Doctoral Research Fellowship. This enabled me to fully concentrate on my academic and clinical development, and afforded access to outstanding training and development opportunities, for which I feel truly fortunate. Finally, to my friends and family, your unquestioning support and understanding has enabled me to maintain my passion, my vision and my focus. I am particularly grateful to my wonderful parents, who helped mould me into the person I have become, while always encouraging me to follow my dreams. I also want to thank my fantastic children, Toby and Ellie; you brighten my life more than you could know! I owe and dedicate this thesis to you all. 6 Contents Table of contents Abstract ........................................................................................................................ 3 Impact statement .......................................................................................................... 4 Acknowledgments ......................................................................................................... 6 Table of contents .......................................................................................................... 7 List of tables ............................................................................................................... 14 List of figures .............................................................................................................. 17 Abbreviations .............................................................................................................. 18 Chapter 1: Overview ..................................................................................................
Load more

Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Quality Use of Medicines in Residential Aged Care
    RESEARCH Quality use of medicines in Michael Somers residential aged care Ella Rose Dasha Simmonds Claire Whitelaw Janine Calver Christopher Beer Background Approximately 190 000 people in high risk of ADEs in frail older people. For example, Older people are more likely to be Australia were estimated to have anticholinergic drugs commonly produce adverse exposed to polypharmacy. People dementia in 2006, with the prevalence effects in elderly people and are more likely to be with dementia, especially those living expected to increase to 465 000 by 2031.1 prescribed to people with dementia than those in residential aged care facilities The prevalence of dementia increases without.7 (RACFs), are at particularly high risk of with age, from 6.5% of Australians aged Antipsychotic medications are commonly used medication harm. We sought to describe medications prescribed for a sample of 65 years and over to 22% of Australians to manage the behavioural and psychological 2 people with dementia living in RACFs. aged 85 years and over. Dementia is symptoms of dementia (BPSD), such as associated with a large burden of disease psychosis, depression, agitation, aggression Methods in Australia’s aging population, costing and disinhibition.1,8 There is concern that A total of 351 residents with dementia Australia $1.4 billion in 2003.2 Most of this antipsychotics are used too frequently as a aged over 65 years were recruited from 36 RACFs in Western Australia. burden was associated with residential first line treatment for BPSD, with the risks of 2 Data on all medications prescribed aged care facilities (RACFs). Dementia antipsychotic use outweighing the benefits at their were collected, including conventional is the medical problem most frequently likely level of use.8 For example, risperidone, an medications, herbal medications, managed by general practitioners atypical antipsychotic prescribed frequently for the vitamins and minerals.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Ambulanter) Pflege (Mupp
    Multimedikation bei älteren Patienten mit (ambulanter) Pflege (MuPP) Gefördert mit Mitteln des LZG.NRW AutorInnen Dr. Veronika Lappe Peter Ihle Dr. Ingrid Schubert Ansprechpartner Dr. Ingrid Schubert, Tel. 0221-478-6545 [email protected] PMV forschungsgruppe Ltg. Dr. I. Schubert Klinik und Poliklinik für Kinder- und Jugendpsychiatrie der Universität zu Köln Herderstraße 52 50931 Köln www.pmvforschungsgruppe.de Mitgliedseinrichtung des Zentrums für Versorgungsforschung Köln (Sprecher Prof. Dr. H. Pfaff) Förderung Die Studie wurde mit Mitteln vom Landeszentrum Gesundheit Nordrhein-Westfalen (AZ34.1.2-GC 05/13) gefördert. Danksagung Die Autoren danken der »AOK NORDWEST – Die Gesund- heitskasse« und der »AOK Rheinland/Hamburg – Die Gesundheitskasse« für die Datenbereitstellung. Hinweis Im Bericht wird aus Gründen der besseren Lesbarkeit für Berufsgruppenbezeichnungen sowie für Patienten und Patientinnen die männliche Form benutzt, die jedoch Frauen wie Männer in gleicherweise mit einschließt. Köln, Februar 2015 Copyright 2015 PMV forschungsgruppe Multimedikation bei Pflege Landeszentrum Gesundheit NRW II In Inhaltsverzeichnis 1 Einleitung 1 1.1 Kontext der Untersuchung 1 1.2 Ziel der Untersuchung 3 2 Material und Methodik 4 2.1 Datenbasis 4 2.2 Studienpopulation 5 2.3 Datenaufbereitung und Definitionen 6 2.3.1 Pflegedaten 6 2.3.2 Arzneimittelverordnungen 6 2.3.3 Definition von Multimedikation 8 2.3.4 Art der Multimedikation 8 2.3.5 Regionale Differenzierung 13 2.4 Verwendete Software und statistische Methoden 14 3 Ergebnisse 15 3.1
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Irish Medicines Board
    Irish Medicines Board IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. No.540 of 2007) PA0167/098/001 Case No: 2063572 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to Baxter Healthcare Limited Caxton Way , Thetford , Norfolk IP24 3SE , United Kingdom an authorisation, subject to the provisions of the said Regulations, in respect of the product CLINIMIX N9G15E, solution for infusion The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 19/05/2009 until 11/12/2009 . Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. ______________________________________________________________________________________________________________________ Date Printed 19/05/2009 CRN 2063572 page number: 1 Irish Medicines Board Part II Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT CLINIMIX ® N9G15E, solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION CLINIMIX ® N9G15E is packaged in a dual compartment plastic bag containing respectively an amino acid solution with electrolytes and a glucose solution with calcium. The injectable amino acid solution contains 15 L -amino acids
    [Show full text]
  • Pileptic Fosphenytoin
    PACKAGE LEAFLET: INFORMATION FOR THE PATIENT TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion Read all of this leaflet carefully before you will be administered this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or nurse. • If you get any side effect, talk to your doctor or nurse. This includes any side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is and what it is used for 2. What you need to know before TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is administered 3. How TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion will be used 4. Possible side effects 5. How TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is stored 6. Contents of the pack and other information 1. What TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is and what it is used for TRIOMEL is an emulsion for infusion. It is presented in a bag with 3 chambers. One chamber contains a glucose solution, the second one contains a lipid emulsion and the third one contains an amino acid solution. TRIOMEL is used to provide nutrition to adults and children greater than 2 years of age by a tube into a vein when normal feeding by mouth is not suitable. TRIOMEL must only be used under medical supervision.
    [Show full text]
  • Summary of Product Characteristics 1. Name Of
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Numeta G19E emulsion for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION This medicinal product is presented in the form of a three chamber bag. Each bag contains a sterile non-pyrogenic combination of a glucose solution, a paediatric amino acids solution, with electrolytes, and a lipid emulsion, as described below. Container size 50% glucose solution 5.9% amino acids solution 12.5% lipid emulsion with electrolytes 1000 mL 383 mL 392 mL 225 mL If lipid administration is undesirable, the design of the bag allows the possibility to activate only the peel seal between the amino acids/electrolytes and glucose chambers, leaving the peel seal between the amino acids and lipid chambers intact. The content of the bag can subsequently be infused with or without lipids. The composition of the drug product after mixing of the two (amino acids and glucose 2 chamber bag, 775 mL solution) or three (amino acids, glucose and lipid 3 chamber bag, 1000 mL emulsion) chambers are provided in the following table. Page 1 of 28 Composition Active Substance Activated 2CB Activated 3CB (775 mL) (1000 mL) Amino Acid Chamber Alanine 1.83 g 1.83 g Arginine 1.92 g 1.92 g Aspartic acid 1.37 g 1.37 g Cysteine 0.43 g 0.43 g Glutamic acid 2.29 g 2.29 g Glycine 0.91 g 0.91 g Histidine 0.87 g 0.87 g Isoleucine 1.53 g 1.53 g Leucine 2.29 g 2.29 g Lysine monohydrate 2.82 g 2.82 g (equivalent to Lysine) (2.51 g) (2.51 g) Methionine 0.55 g 0.55 g Ornithine hydrochloride 0.73 g 0.73 g (equivalent to Ornithine)
    [Show full text]
  • Health Effects of Labor Market Policies: Evidence from Drug Prescriptions
    Health Effects of Labor Market Policies: Evidence from Drug Prescriptions Marco Caliendo∗ Robert Mahlstedty Gerard J. van den Bergz teststets Johan Vikstr¨omx Preliminary Version This draft: November 13, 2019 -Please do not cite or circulate- We exploit individual-level labor market and prescription drug records to study unintended effects of labor market policies on participants' health status. We examine two popular and commonly used interventions that represent different reintegration strategies for unemployed workers: training programs and benefit sanctions. To establish a causal relationship we ex- ploit the longitudinal aspect of the prescription records and estimate dynamic difference- in-differences models comparing treated and non-treated individuals before and after the treatment. Our results show that supportive interventions, such as training programs, re- duce drug prescriptions related to cardiovascular and mental health diseases by about 6-7% within a year after the program start. The direct effect of participating, e.g. due to a change of daily routines, seem to be more important than the indirect effect through improved em- ployment prospects. Restrictive interventions, such as benefit sanctions, have no long-lasting effects on drug prescriptions, but the notification of an upcoming sanction leads to a short- term increase in prescriptions for mental health issues, which is possible induced by higher stress levels. Keywords: Unemployment, Labor market policies, Health Effects JEL codes: J68, I12, I18, H51 ∗University of Potsdam, IZA Bonn, DIW Berlin, IAB Nuremberg; [email protected] yUniversity of Copenhagen and IZA Bonn; [email protected] Corresponding address: University of Copenhagen, Department of Economics, Øster Farimagsgade 5, 1353 Copen- hagen K, Denmark.
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Downloads/Solutio%20Comprehensive%20Formulary Nov06.Xls
    DEPRESSIVE DISORDERS AND CHRONIC COMORBID DISEASE STATES – A PHARMACOEPIDEMIOLOGICAL EVALUATION LIA KRITIOTIS DEPRESSIVE DISORDERS AND CHRONIC COMORBID DISEASE STATES – A PHARMACOEPIDEMIOLOGICAL EVALUATION LIA KRITIOTIS submitted in fulfilment of the requirements for the degree of MAGISTER SCIENTIAE in the FACULTY OF HEALTH SCIENCES at the NELSON MANDELA METROPOLITAN UNIVERSITY February 2007 Supervisor: Dr M Bellingan Co-supervisor: Prof I Truter I, Lia Kritiotis, hereby declare that the work on which this dissertation is based is original (except where acknowledgements indicate otherwise) and that neither the whole work nor any part of it has been, is being, or is to be submitted for another degree at this or any other university. ACKNOWLEDGEMENTS I am extremely grateful for having had the opportunity to conduct this study and would like to extend my sincere appreciation to the following people and institutions for making it possible for me to carry out this research: • Doctor Michelle Bellingan, my supervisor, for sharing her interest, advice and expertise regarding the field of Depressive Disorders, and for the guidance and encouragement shown throughout the study. On a more personal level, thank you for being a great teacher of the language of life. • Professor Ilse Truter, my co-supervisor, for her continuous support and motivation, and for her invaluable advice, which stems from a vast knowledge and experience in terms of drug utilisation reviews. In addition, thank you for being there when the language of life was difficult to interpret across the miles. • Mr Danie Venter for the time he dedicated towards broadening my statistical knowledge and for his assistance in this regard.
    [Show full text]
  • Analyses of Spontaneous Adverse Drug Reaction Databases Using Descriptive and Inferential Statistics
    Analyses of Spontaneous Adverse Drug Reaction Databases Using Descriptive and Inferential Statistics Dissertation zur Erlangung des Doktorgrades (PhD) der Medizinischen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn Diana Ivonne Dubrall aus Heidenheim an der Brenz 2020 Angefertigt mit der Genehmigung der Medizinischen Fakultät der Universität Bonn 1. Gutachter: Prof. Dr. rer. nat. Matthias Schmid 2. Gutachter: Prof. Dr. med. Bernhardt Sachs Tag der mündlichen Prüfung: 04.09.2020 Aus dem Institut für Medizinische Biometrie, Informatik und Epidemiologie Direktor: Prof. Dr. rer. nat. Matthias Schmid 3 Table of content Table of content ........................................................................................................ 3 List of abbreviations ................................................................................................. 4 1. Summary ............................................................................................................... 5 2. Introduction ........................................................................................................... 5 3. Objectives ............................................................................................................. 8 4. Methods ................................................................................................................. 8 4.1 BfArM’s ADR database ...................................................................................... 8 4.2 EudraVigilance .................................................................................................
    [Show full text]